Literature DB >> 12691465

Mathematical modeling of viral kinetics: a tool to understand and optimize therapy.

Thomas J Layden1, Jennifer E Layden, Ruy M Ribeiro, Alan S Perelson.   

Abstract

One theme that continues to emerge from these studies is the relevance and need for a strong IFN effectiveness. In the prediction studies, the importance of IFN effectiveness for eventual clearance of the virus is present. In the study by Layden et al, the relevance of the viral load at the end of the first phase and IFN effectiveness, to the subsequent second-phase viral decline, is discussed. In the recently developed triphasic model by Bergmann et al, it is illustrated how, theoretically, the viral load at the end of the first phase could impact the second-phase viral decline and eventual clearance of the virus. And, in the investigation into the difference in viral dynamics between African Americans and Caucasians, it appears that a strong effectiveness and first-phase log drop is crucial for virus eradication. More work needs to be completed to understand better why the effectiveness is so crucial for elimination of the virus, and why the effectiveness varies so significantly from one person to another, or from one genotype to another. In a rather short time, the study of viral kinetics has improved our understanding of HCV infection, especially in relation to treatment response. Information has been gleaned on the rapid turnover and clearance rate of the virus, the mode of action of IFN, and the dose-dependence of IFN in inhibiting viral production. Such information has been used to challenge the way we treat patients, understand the difference between nonresponders and responders, gain insight into possible mechanisms of treatment resistance, and predict treatment response. As newer drugs emerge, viral kinetic studies should be able to shed light on the dose-dependent efficacy and mode of action of these newer forms of therapy. The use of kinetics needs to be extended to other areas, such as the study and treatment of acute HCV infection as well as following liver transplantation (see article by Drs. Pawlotsky and Rosen). If the past is any indication of the usefulness of mathematical modeling and kinetics in the study of viruses, continued employment of these tools will only prove beneficial.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691465     DOI: 10.1016/s1089-3261(02)00063-6

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  17 in total

1.  Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.

Authors:  Joshua N Leonard; David V Schaffer
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

2.  Senescence and antibiotic resistance in an age-structured population model.

Authors:  Patrick De Leenheer; Jack Dockery; Tomás Gedeon; Sergei S Pilyugin
Journal:  J Math Biol       Date:  2009-11-12       Impact factor: 2.259

3.  A mathematical model of HIV dynamics in the presence of a rescuing virus with replication deficiency.

Authors:  Elias Zintzaras; Axel Kowald
Journal:  Theory Biosci       Date:  2011-01-29       Impact factor: 1.919

Review 4.  Multiscale modeling for biologists.

Authors:  Martin Meier-Schellersheim; Iain D C Fraser; Frederick Klauschen
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2009 Jul-Aug

Review 5.  Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.

Authors:  Libin Rong; Alan S Perelson
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

6.  Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis.

Authors:  A J Demetris; B Eghtesad; A Marcos; K Ruppert; M A Nalesnik; P Randhawa; T Wu; A Krasinskas; P Fontes; T Cacciarelli; A O Shakil; N Murase; J J Fung; T E Starzl
Journal:  Am J Surg Pathol       Date:  2004-05       Impact factor: 6.394

Review 7.  Chronic hepatitis C in African Americans and other minority groups.

Authors:  Jaquelyn Fleckenstein
Journal:  Curr Gastroenterol Rep       Date:  2004-02

Review 8.  Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches.

Authors:  Arnon Arazi; William F Pendergraft; Ruy M Ribeiro; Alan S Perelson; Nir Hacohen
Journal:  Semin Immunol       Date:  2013-01-29       Impact factor: 11.130

Review 9.  Nonresponse to treatment for hepatitis C: current management strategies.

Authors:  He-Jun Yuan; William M Lee
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).

Authors:  Adriana Andrade; Jeremie Guedj; Susan L Rosenkranz; Darlene Lu; John Mellors; Daniel R Kuritzkes; Alan S Perelson; Ruy M Ribeiro
Journal:  AIDS       Date:  2015-11-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.